NEDD9 depletion destabilizes aurora a kinase and heightens the efficacy of aurora a inhibitors: Implications for treatment of metastatic solid tumors

Cancer Research

Volumn 73, Issue 10, 2013, Pages 3168-3180

  Ice, Ryan J ^d   Mclaughlin, Sarah L ^d   Livengood, Ryan H ^c   Culp, Mark V ^b   Eddy, Erik R ^b   Ivanov, Alexey V ^a,d   Pugacheva, Elena N ^a,d,e  

^a Departments of Biochemistry   (United States)

^b Departments of Statistics   (United States)

^c University of Colorado Anschutz Medical Campus   (United States)

^d WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALISERTIB; AURORA A KINASE; MESSENGER RNA; NEDD9 PROTEIN; PLACEBO; PROTEASOME; REGULATOR PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AURORA A KINASE GENE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SOLID TUMOR; TISSUE MICROARRAY; TUMOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT; UBIQUITINATION; WILD TYPE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; ENZYME STABILITY; FEMALE; HUMANS; MICE; NEOPLASM METASTASIS; PHOSPHOPROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877843428     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4008     Document Type: Article

References (37)

1. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20: 189-93. (Pubitemid 28455454)
2. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997;14:2195-200. (Pubitemid 27248231)
3. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65. (Pubitemid 28254378)
4. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008;14:4455-62.
5. Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, et al. The role of Aurora-A inhibitors in cancer therapy. Ann Oncol 2007;18:vi47-52.
6. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999;59:2041-4. (Pubitemid 29217660)
7. Taguchi Si, Honda K, Sugiura K, Yamaguchi A, Furukawa K, Urano T. Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Lett 2002;519:59-65. (Pubitemid 34521992)
8. Floyd S, Pines J, Lindon C. APC/C(Cdh1) targets aurora kinase to control reorganization of the mitotic spindle at anaphase. Curr Biol 2008;18:1649-58.
9. Crane R, Kloepfer A, Ruderman JV. Requirements for the destruction of human Aurora-A. J Cell Sci 2004;117:5975-83. (Pubitemid 40123964)
10. Tyers M, Jorgensen P. Proteolysis and the cell cycle: With this RING I do thee destroy. Curr Opin Genet Dev 2000;10:54-64. (Pubitemid 30113706)
11. Zachariae W. Progression into and out of mitosis. Curr Opin Cell Biol 1999;11:708-16.
12. Shi Y, Solomon LR, Pereda-Lopez A, Giranda VL, Luo Y, Johnson EF, et al. Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A. J Biol Chem 2011;286:38960-8.
13. Giubettini M, Asteriti IA, Scrofani J, De Luca M, Lindon C, Lavia P, et al. Control of Aurora-A stability through interaction with TPX2. J Cell Sci 2011;124:113-22.
14. Huang YH, Wu CC, Chou CK, Huang CY. A translational regulator, PUM2, promotes both protein stability and kinase activity of Aurora-A. PLoS ONE 2011;6:e19718.
15. Johnson EO, Chang KH, Ghosh S, Venkatesh C, Giger K, Low PS, et al. LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy. J Cell Sci 2012;125:1204-16.
16. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24. (Pubitemid 41112921)
17. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 2007;104:6740-5. (Pubitemid 47175571)
18. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81. (Pubitemid 43949521)
19. Pugacheva EN, Golemis EA. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol 2005;7:937-46. (Pubitemid 41486266)
20. Nourry C, Maksumova L, Pang M, Liu X, Wang T. Direct interaction between Smad3, APC10, CDH1 and HEF1 in proteasomal degradation of HEF1. BMC Cell Biol 2004;5:20.
21. Zheng M, McKeown-Longo PJ. Cell adhesion regulates Ser/Thr phosphorylation and proteasomal degradation of HEF1. J Cell Sci 2006;119:96-103. (Pubitemid 43169302)
22. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6: 3158-68.
23. Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006;12:4080-9. (Pubitemid 44078096)
24. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007;27:4513-25. (Pubitemid 46906573)
25. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, et al. Phase 1 study of MLN8054, a selective inhibitor of AuroraAkinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:945-54.
26. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007;129:1351-63. (Pubitemid 46962087)
27. Ruijter JM, Pfaffl MW, Zhao S, Spiess AN, Boggy G, Blom J, et al. Evaluation of qPCR curve analysis methods for reliable biomarker discovery: Bias, resolution, precision, and implications. Methods 2013;59:32-46.
28. Pugacheva EN, Golemis EA. HEF1-aurora A interactions: Points of dialog between the cell cycle and cell attachment signaling networks. Cell Cycle 2006;5:384-91.
29. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55: 26-34.
30. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011;17:7614-24.
31. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity ofMLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104: 4106-11. (Pubitemid 47181586)
32. Kasap E, Boyacioglu SO, Korkmaz M, Yuksel ES, Unsal B, Kahraman E, et al. Aurora kinase A (AURKA) and never in mitosis gene Arelated kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma. Exp Ther Med 2012;4: 33-42.
33. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-98. (Pubitemid 37159255)
34. Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich JA. Mitotic activation of the kinase Aurora-A requires its binding partner Bora. Dev Cell 2006;11:147-57. (Pubitemid 44138495)
35. Tsai MY, Wiese C, Cao K, Martin O, Donovan P, Ruderman J, et al. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly Nat. Cell Biol 2003;5:242-8. (Pubitemid 36322252)
36. Chan EH, Santamaria A, Sillj-e HW, Nigg EA. Plk1 regulates mitotic Aurora A function through bTrCP-dependent degradation of hBora. Chromosoma 2008;117:457-69.
37. Macurek L, Lindqvist A, Medema RH. Aurora-A and hBora join the game of Polo. Cancer Res 2009;69:4555-8.